Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump
U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling around 400 points on Friday.
44 Stocks Moving In Friday’s Mid-Day Session
Gainers
Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Mid-Morning Market Update: Markets Open Lower; US Inflation Rate Accelerates to 8.6%
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Friday.
25 Stocks Moving in Friday’s Pre-Market Session
Gainers
Regis Corporation (NYSE: RGS) rose 74.4% to $0.9753 in pre-market trading. Regis partnered with salon technology provider Zenoti to support its 5,000+ locations.
Looking Into Caribou Biosciences’s Return On Capital Employed
Benzinga Pro data, Caribou Biosciences (NASDAQ:CRBU) reported Q1 sales of $2.66 million. Earnings fell to a loss of $19.09 million, resulting in a 3.3% decrease from last quarter.
Caribou Biosciences Presents Data On Mechanism Underlying Superior Specificity Of Caribou’s chRDNA Genome-Editing Technology In Primary Human T cells
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of studies in primary human T cells highlighting the mechanism
90 Biggest Movers From Yesterday
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
58 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Caribou’s Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress.